US Healthcare Agency Ditches Human Fetal Tissue in Research Funding
In a significant policy shift, the National Institutes of Health (NIH) announced on Thursday that it will no longer fund research using human fetal tissue obtained from elective abortions. The decision marks a major victory for anti-abortion advocates who have long campaigned against such research.
The NIH's decision takes effect immediately and is part of an effort to modernize the agency's approach to biomedical research, according to Jay Bhattacharya, the NIH's director. According to Bhattacharya, this move is aimed at investing in breakthrough technologies that can better model human health and disease.
While the number of NIH-backed projects involving fetal tissue from abortions has been declining since 2019, with only 77 such projects receiving funding in fiscal year 2024 for a total of $60 million, critics argue that alternative sources of tissue are often more difficult to obtain. Fetal tissue obtained from miscarriages, for instance, may be tainted by genetic or chromosomal abnormalities that make it unsuitable for research.
The NIH's decision follows a series of moves aimed at restricting the use of fetal tissue in research. In 2019, during Donald Trump's presidency, the agency stopped funding internal research involving fetal tissue and established a review committee to evaluate proposals from outside scientists. The policy was reversed by Joe Biden in 2021.
Fetal tissue has played a crucial role in advancing research into various diseases, including diabetes, Alzheimer's, and infertility. It has also contributed to the development of vaccines for polio, hepatitis A, rabies, and other illnesses. Despite its importance, the use of human fetal tissue in research remains highly contentious among pro-life activists and scientists alike.
In a significant policy shift, the National Institutes of Health (NIH) announced on Thursday that it will no longer fund research using human fetal tissue obtained from elective abortions. The decision marks a major victory for anti-abortion advocates who have long campaigned against such research.
The NIH's decision takes effect immediately and is part of an effort to modernize the agency's approach to biomedical research, according to Jay Bhattacharya, the NIH's director. According to Bhattacharya, this move is aimed at investing in breakthrough technologies that can better model human health and disease.
While the number of NIH-backed projects involving fetal tissue from abortions has been declining since 2019, with only 77 such projects receiving funding in fiscal year 2024 for a total of $60 million, critics argue that alternative sources of tissue are often more difficult to obtain. Fetal tissue obtained from miscarriages, for instance, may be tainted by genetic or chromosomal abnormalities that make it unsuitable for research.
The NIH's decision follows a series of moves aimed at restricting the use of fetal tissue in research. In 2019, during Donald Trump's presidency, the agency stopped funding internal research involving fetal tissue and established a review committee to evaluate proposals from outside scientists. The policy was reversed by Joe Biden in 2021.
Fetal tissue has played a crucial role in advancing research into various diseases, including diabetes, Alzheimer's, and infertility. It has also contributed to the development of vaccines for polio, hepatitis A, rabies, and other illnesses. Despite its importance, the use of human fetal tissue in research remains highly contentious among pro-life activists and scientists alike.